BridgeBio Pharma Operating Income 2018-2026 | BBIO
BridgeBio Pharma annual/quarterly operating income history and growth rate from 2018 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- BridgeBio Pharma operating income for the quarter ending June 30, 2026 was $-0.107B, a 20.26% decline year-over-year.
- BridgeBio Pharma operating income for the twelve months ending June 30, 2026 was $-0.498B, a 24.17% decline year-over-year.
- BridgeBio Pharma annual operating income for 2025 was $-0.523B, a 11.73% decline from 2024.
- BridgeBio Pharma annual operating income for 2024 was $-0.593B, a 2.37% decline from 2023.
- BridgeBio Pharma annual operating income for 2023 was $-0.607B, a 18.58% increase from 2022.
|
BridgeBio Pharma Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $-523 |
| 2024 | $-593 |
| 2023 | $-607 |
| 2022 | $-512 |
| 2021 | $-577 |
| 2020 | $-474 |
| 2019 | $-266 |
| 2018 | $-184 |
| 2017 | $-44 |
|
BridgeBio Pharma Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-107 |
| 2026-03-31 | $-106 |
| 2025-12-31 | $-140 |
| 2025-09-30 | $-145 |
| 2025-06-30 | $-134 |
| 2025-03-31 | $-104 |
| 2024-12-31 | $-226 |
| 2024-09-30 | $-192 |
| 2024-06-30 | $-176 |
| 2024-03-31 | $0 |
| 2023-12-31 | $-177 |
| 2023-09-30 | $-158 |
| 2023-06-30 | $-146 |
| 2023-03-31 | $-126 |
| 2022-12-31 | $-129 |
| 2022-09-30 | $-129 |
| 2022-06-30 | $-80 |
| 2022-03-31 | $-174 |
| 2021-12-31 | $-166 |
| 2021-09-30 | $-149 |
| 2021-06-30 | $-94 |
| 2021-03-31 | $-168 |
| 2020-12-31 | $-127 |
| 2020-09-30 | $-120 |
| 2020-06-30 | $-125 |
| 2020-03-31 | $-102 |
| 2019-12-31 | $-79 |
| 2019-09-30 | $-55 |
| 2019-06-30 | $-69 |
| 2019-03-31 | $-64 |
| 2018-09-30 | $-41 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |